ArticleACS applied materials & interfaces2025
Selenium Nanoparticles-Encapsulated Exosomes That Mitigate Acute Liver Injury via an Oral Carboxymethyl Chitosan/Oxidized Dextran Hydrogel.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond immunomodulation: mechanisms and synergistic strategies of mesenchymal stem cells in promoting alveolar epithelial and endothelial repair in ARDS.Frontiers in immunology · 2026Review
- Plant Exosome-Loaded Intelligent Hydrogels for Osteoporotic Bone Regeneration: Mechanisms and Applications.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute liver injury (ALI), a major global health concern, is associated with limited therapeutic options due to the absence of specific drugs. The key pathological features of ALI, including acute oxidative stress and impaired liver function, provide targets for therapeutic interventions. Herein, an innovative strategy was developed that combines selenium nanoparticles (SeNPs) with mesenchymal stem cell-derived exosomes (MSCs-Exos), utilizing their antioxidant and regenerative properties. In addition, to improve SeNP stability and minimize the rapid in vivo clearance of MSCs-Exos, a stable hydrogel-based delivery platform (Hydrogel-Exos-SeNPs) was designed. The Hydrogel-Exos-SeNPs system demonstrated excellent stability and effectively delivered Exo-SeNPs into liver cells. Subsequent in vivo experiments confirmed that this system significantly alleviated liver damage by enhancing liver function, suppressing oxidative stress, and accelerating regeneration. This study presents an oral SeNPs-Exos delivery system as a novel approach to mitigate ALI and restore liver function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.